In conclusion, several cancers with JAK2/STAT overactivation, either induced by growth factor stimulation or by receptor mutations, could benefit from HSP90 or HSP27 targeting alone or in combination with JAK2 targeting therapies. The gene discussed is HSPB3; the disease is cancer.